Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Can Marketers Learn From Botox?

What once started as a party favor at glamorous Hollywood parties in the 1950s has taken the medical world by storm lately. Cosmetically, the Botox industry is booming, and millennials are embracing it. However, the drug has benefits far beyond the scope of its well-known aesthetic perks. Clinical trials and patient responses have proved Botox…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

What once started as a party favor at glamorous Hollywood parties in the 1950s has taken the medical world by storm lately. Cosmetically, the Botox industry is booming, and millennials are embracing it. However, the drug has benefits far beyond the scope of its well-known aesthetic perks.

Clinical trials and patient responses have proved Botox effective for treating several medical conditions including Parkinson’s disease, chronic migraines, hyperhidrosis, overactive bladder and even depression.

“Botox is the only medicine FDA approved for chronic migraine…it has a 30-year safety record and the side effects are almost zero,” Dr. Peter McAllister, Co-Founder and Chief Medical Officer at the New England Center for Neurology and Headache said.

McAllister was a vital contributor to the original Botox clinical trial and is a “Top Neurologist” according to U.S. News and World Report. His devotion to re-purposing this drug has created a revolution in the chronic migraine world considering there are few treatments for the condition– one that is debilitating and widespread.

Repairing a Reputation

To best define a business model for maximizing its medical future, we must examine the drug’s history and recreational reputation.

Though this trend has become mainstream, it was not always this way. Historically, consumers would do anything to pass their latest Botox treatment off as a magical serum before confessing the truth. There will always be a lingering type of faux modesty and judgement that comes with cosmetic surgery.

This judgement has been an integral part of the drug’s newfound success, and society has undergone a strong attempt at what looks like the erosion of the stigma surrounding Botox and other cosmetic surgeries.

According to the American Society of Plastic Surgeons, Botox has increased more than 800% since 2002. The effects of the normalization of a product like this can affect other areas of the business world. Though this product itself does not directly affect every industry, its rebrand can be a beacon for other products looking to enter new markets. When any product with a negative connotation is repurposed, the marketing around it must be contrived so mindfully that it protects against individuals who overlook its newfound benefits. In this case, it can change lives.

Marketing Medicine

Botox is the new black. This comes with a whole new set of challenges for individuals looking to rally this drug to reach its full medical potential. The perceived reality of medical aesthetics lies in a hard place. Where is the medium between the generation conditioned to believe Botox exists for vain aesthetic, and the medical frontrunners who see a great product, but little strategy for how to market it to its potential?

Marketing products with unexpected benefits is a challenge in any category. However, the somewhat superficial reputation that comes with Botox’s original purpose makes it difficult to effectively market to its homoeopathic audience.

Bluntly put, this drug saves lives and the judgement that comes with its original purpose should not make those in need of this treatment unwilling to try it.

The first step towards encouraging patients to see its maximized benefits is changing consumer perception. Medical professionals must work to fuel this movement with thought leadership and digital innovation. They must also come up with ways to increase engagement and decrease stigma-based bias.

The Future of Botox’s Public Perception

While the participation of medical professionals is vital in Botox’s marketing transformation, efforts from existing patients is central. Customer testimonials have the potential to play a huge role in encouraging the public to try medical Botox.

Ninety-seven percent of consumers say customer testimonials influence a buying decision (Fan and Fuel, 2016). Glorifying the already glorious experiences of those using the drugs will aid in supporting the repurposed product.

Some people may be hesitant to undergo a procedure, but Dr. McAllister explains the other side of consumer reception.

“Others think just the opposite…It’s safe and widely used for cosmetic so it must be OK for me,” Dr. McAllister said.

This lateral angle is a huge step in the right direction. Businesses, medical professionals, and consumers must also capitalize on this existing side of the dialogue. The continuation of this societal trend, which has nearly normalized Botox, is backing for its medical application. Carefully positioning this product to steer away from “plastic surgery” and aiming more towards a routine cosmetic procedure as simple as getting a manicure is in the best interest of all B2B stakeholders and will actually help to extend its success in the medical world.

This revolution is not so much about ensuring Botox is solely viewed as a medical treatment. Instead, how can professionals ensure each target market sees it for its desired purpose?

For the latest healthcare news, head to our industry page! You can also follow us on Twitter at @HealthMKSL! Join the conversation in our Market Leaders LinkedIn groups today!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512